Clustering Biotech: A Recipe for Success? Spatial Patterns of Growth of Biotechnology in Munich, Rhineland and Hamburg
By Christian Zeller. 2001
123 citations recorded by the source corpus.
Subfields: Economics and Econometrics, Sociology and Political Science, Strategy and Management
View Paper: https://www.semanticscholar.org/paper/2c4cea5a7c7890d0d48dcb01d231f30db54faa7b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Economics and Econometrics
- A. Malmberg
- Lars Coenen
- D. Power
- Jerker Moodysson
- Maryann P. Feldman
- N. Evers
- Bjørn T. Asheim
- Svante Andersson
In Sociology and Political Science
- Svante Andersson
- A. Malmberg
- Maryann P. Feldman
- Lars Coenen
- D. Power
- N. Evers
- Jerker Moodysson
- A. Scott
In Strategy and Management
- Lars Coenen
- Jerker Moodysson
- N. Evers
- Bjørn T. Asheim
- A. Malmberg
- D. Power
- Clémence Griot
- Svante Andersson
Citations in the corpus
- The Locational Dynamics of the U.S. Biotech Industry: Knowledge Externalities and the Anchor Hypothesis (2005, background): “Evidence on the location of the biotech industry highlights the importance of the location of the chemical and pharmaceutical industry, especially their headquarters and R&D labs (Gray and Parker 1998; Orsenigo 2001:81-82; Zeller 2001).”
- (How) Do (Firms in) Clusters Create Knowledge? (2005, background): “Zhang (2003) emphasizes that high-tech industrial clusters are characterized by concentrated 420 A.”
- Nodes, networks and proximities: on the knowledge dynamics of the Medicon Valley biotech cluster (2004, background): “In the German biotech industry Zeller (2001) finds that interactive innovative relations exist on very different spatial scales.”
- Local and international networks in small firm internationalization: cases from the Rhône-Alpes medical technology regional cluster (2013, background): “Zeller (2001) maintains that medical biotechnology firms seek alliances with international pharmaceutical firms.”